These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23036797)

  • 1. Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients.
    Watters AL; Hansen HJ; Williams T; Chou JF; Riedel E; Halpern J; Tunick S; Bohle G; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Feb; 115(2):192-200. PubMed ID: 23036797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
    Nicolatou-Galitis O; Papadopoulou E; Sarri T; Boziari P; Karayianni A; Kyrtsonis MC; Repousis P; Barbounis V; Migliorati CA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Aug; 112(2):195-202. PubMed ID: 21622014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
    Thumbigere-Math V; Tu L; Huckabay S; Dudek AZ; Lunos S; Basi DL; Hughes PJ; Leach JW; Swenson KK; Gopalakrishnan R
    Am J Clin Oncol; 2012 Aug; 35(4):386-92. PubMed ID: 22561331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
    Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F
    Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases.
    Pelaz A; Junquera L; Gallego L; García-Consuegra L; García-Martínez L; Cutilli T; Olay S
    Acta Otorrinolaringol Esp; 2015; 66(3):139-47. PubMed ID: 25308796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.
    Rugani P; Luschin G; Jakse N; Kirnbauer B; Lang U; Acham S
    Clin Oral Investig; 2014; 18(2):401-7. PubMed ID: 23749244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
    Martins MA; Martins MD; Lascala CA; Curi MM; Migliorati CA; Tenis CA; Marques MM
    Oral Oncol; 2012 Jan; 48(1):79-84. PubMed ID: 21940198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan.
    Urade M; Tanaka N; Furusawa K; Shimada J; Shibata T; Kirita T; Yamamoto T; Ikebe T; Kitagawa Y; Fukuta J
    J Oral Maxillofac Surg; 2011 Nov; 69(11):e364-71. PubMed ID: 21782307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis?
    Lescaille G; Coudert AE; Baaroun V; Javelot MJ; Cohen-Solal M; Berdal A; Goudot P; Azérad J; Ruhin B; Descroix V
    J Rheumatol; 2013 Jun; 40(6):781-6. PubMed ID: 23504384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation.
    Then C; Hörauf N; Otto S; Pautke C; von Tresckow E; Röhnisch T; Baumann P; Schmidmaier R; Bumeder I; Oduncu FS
    Onkologie; 2012; 35(11):658-64. PubMed ID: 23147542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years.
    Mücke T; Deppe H; Hein J; Wolff KD; Mitchell DA; Kesting MR; Retz M; Gschwend JE; Thalgott M
    J Craniomaxillofac Surg; 2016 Oct; 44(10):1689-1693. PubMed ID: 27555374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
    Lazarovici TS; Yahalom R; Taicher S; Elad S; Hardan I; Yarom N
    J Oral Maxillofac Surg; 2009 Apr; 67(4):850-5. PubMed ID: 19304045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.
    Katz J; Ordoveza PA
    Quintessence Int; 2014 Sep; 45(8):685-90. PubMed ID: 25019116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients.
    Thumbigere-Math V; Sabino MC; Gopalakrishnan R; Huckabay S; Dudek AZ; Basu S; Hughes PJ; Michalowicz BS; Leach JW; Swenson KK; Swift JQ; Adkinson C; Basi DL
    J Oral Maxillofac Surg; 2009 Sep; 67(9):1904-13. PubMed ID: 19686928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III.
    Bodem JP; Schaal C; Kargus S; Saure D; Mertens C; Engel M; Hoffmann J; Freudlsperger C
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Apr; 121(4):367-72. PubMed ID: 26795450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.